

10 January 2023

ASX Announcement

Second Japan patent for AD-214

MELBOURNE Australia, 10 January 2023: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to announce that a second Japanese patent relating to lead program, AD-214, has been granted by the Japanese Patent Office.

Patent Number 2020-121974, entitled “CXCR4 binding molecules”, has an expiry date of 8 January 2036.

The patent is directed to polypeptides containing the binding loops of the company’s lead i-body AD-214 that have variation in the i-body scaffold sequence and thus the patent coverage extends to i-bodies that are related to AD-214 for treating CXCR4-related diseases or disorders. This includes the lead indication of idiopathic pulmonary fibrosis as well as cancer, viral infections, inflammatory diseases, sclerosis, kidney disease, eye disorders and immune deficiency disorders and wounds.

This patent extends the range and diversity of sequences analogous to AD-214 that are protected.

AdAlta’s CEO and Managing Director, Dr Tim Oldham said:

“Japan is the third largest pharmaceutical market in the world and remains important to our partnering and commercialisation strategy. This patent is a valuable, additional piece of intellectual property which enables expansion of protected claims for AD-214 in Japan, a major market for fibrosis-related diseases.”

This is the second patent granted in Japan for AD-214, adding to existing patent protection. Patents for the asset also exist in the U.S., Europe, China, Australia, India, Hong Kong and Singapore.

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
January 2023

Notes to Editors

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in pre-clinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au